Page last updated: 2024-10-19

niacinamide and Carcinogenesis

niacinamide has been researched along with Carcinogenesis in 16 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Carcinogenesis: The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.

Research Excerpts

ExcerptRelevanceReference
"Aim of the study was to investigate efficacy and safety of sorafenib in patients with advanced lung adenocarcinoma after failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy."9.19A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805). ( Chen, GY; Cheng, Y; Huang, C; Li, AW; Su, J; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Zhang, L; Zhang, XC; Zhou, CC; Zhou, Q, 2014)
"Sorafenib is a small molecule multikinase inhibitor that acts against different cancer cell lines and is used for the treatment of HCC."5.46Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation. ( He, J; Liu, P; Lv, X; Wang, L; Xu, X; Yan, Y; Zhang, L; Zhang, Y, 2017)
"Aim of the study was to investigate efficacy and safety of sorafenib in patients with advanced lung adenocarcinoma after failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy."5.19A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805). ( Chen, GY; Cheng, Y; Huang, C; Li, AW; Su, J; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Zhang, L; Zhang, XC; Zhou, CC; Zhou, Q, 2014)
"Nicotinamide metabolism is important in carcinogenesis."3.01Nicotinamide N-methyl transferase and cancer-associated thrombosis: insights to prevention and management. ( Ardakany, MR; Ebrahimi, S; Jabbari, P; Rezaei, N, 2023)
"Sorafenib is a small molecule multikinase inhibitor that acts against different cancer cell lines and is used for the treatment of HCC."1.46Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation. ( He, J; Liu, P; Lv, X; Wang, L; Xu, X; Yan, Y; Zhang, L; Zhang, Y, 2017)
"Sorafenib is an orally active multikinase tyrosine kinase inhibitor (TKI) that targets B-type Raf kinase (BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged during transfection (RET), inducing anti-angiogenic and pro-apoptotic actions in a wide range of solid tumors."1.43(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges. ( Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JWA; van der Hoeven, JJM; van Wezel, T, 2016)
"Human hepatoma cells stably expressing short hairpin RNA targeting AR and cells over-expressing AR were generated."1.40Involvement of androgen receptor and glucose-regulated protein 78 kDa in human hepatocarcinogenesis. ( Jiang, X; Kanda, T; Miyamura, T; Nakamoto, S; Wu, S; Yokosuka, O, 2014)
"Pediatric ependymomas are highly recurrent tumors resistant to conventional chemotherapy."1.40Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. ( Adamski, J; Agnihotri, S; Barszczyk, M; Buczkowicz, P; Castelo-Branco, P; Dirks, PB; Elizabeth, C; Golbourn, B; Hawkins, C; Li, XN; Luu, B; Mack, SC; Mangerel, J; Morrison, A; Nethery-Brokx, K; Pajovic, S; Ramaswamy, V; Remke, M; Rutka, JT; Tabori, U; Taylor, MD; Van Meter, T; Yu, M, 2014)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19901 (6.25)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's13 (81.25)24.3611
2020's2 (12.50)2.80

Authors

AuthorsStudies
Hofer, SJ1
Kroemer, G1
Kepp, O1
Jabbari, P1
Ardakany, MR1
Ebrahimi, S1
Rezaei, N1
DeWaal, D1
Nogueira, V1
Terry, AR1
Patra, KC1
Jeon, SM1
Guzman, G1
Au, J1
Long, CP1
Antoniewicz, MR1
Hay, N1
Minocha, R1
Martin, AJ1
Chen, AC2
Scolyer, RA1
Lyons, JG1
McKenzie, CA1
Madore, J1
Halliday, GM1
Damian, DL2
Galbraith, AR1
Seabloom, DE1
Wuertz, BR1
Antonides, JD1
Steele, VE1
Wattenberg, LW1
Ondrey, FG1
Zhou, Q1
Zhou, CC1
Chen, GY1
Cheng, Y1
Huang, C1
Zhang, L2
Xu, CR1
Li, AW1
Yan, HH1
Su, J1
Zhang, XC1
Yang, JJ1
Wu, YL1
Jiang, X1
Kanda, T1
Nakamoto, S1
Miyamura, T1
Wu, S1
Yokosuka, O1
Barszczyk, M1
Buczkowicz, P1
Castelo-Branco, P1
Mack, SC1
Ramaswamy, V1
Mangerel, J1
Agnihotri, S1
Remke, M1
Golbourn, B1
Pajovic, S1
Elizabeth, C1
Yu, M1
Luu, B1
Morrison, A1
Adamski, J1
Nethery-Brokx, K1
Li, XN1
Van Meter, T1
Dirks, PB1
Rutka, JT1
Taylor, MD1
Tabori, U1
Hawkins, C1
Tang, W1
Xue, R1
Weng, S1
Wu, J1
Fang, Y1
Wang, Y1
Ji, L1
Hu, T1
Liu, T1
Huang, X1
Chen, S1
Shen, X1
Zhang, S1
Dong, L1
Tiwari, P1
Sahay, S1
Pandey, M1
Qadri, SS1
Gupta, KP1
Delire, B1
Stärkel, P1
Wu, G1
Wilson, G1
Zhou, G1
Hebbard, L1
George, J1
Qiao, L1
Schneider, TC1
Kapiteijn, E1
van Wezel, T1
Smit, JWA1
van der Hoeven, JJM1
Morreau, H1
Yan, Y1
Wang, L1
He, J1
Liu, P1
Lv, X1
Zhang, Y2
Xu, X1
MATUYAMA, M1
NAGAYO, T1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Study of Sorafenib (BAY 43-9006®) in Patients With Relapsed Advanced Non-Small Cell Lung Cancer(NSCLC) After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)Treatment[NCT00922584]Phase 265 participants (Actual)Interventional2008-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

3 reviews available for niacinamide and Carcinogenesis

ArticleYear
Nicotinamide N-methyl transferase and cancer-associated thrombosis: insights to prevention and management.
    Epigenomics, 2023, Volume: 15, Issue:6

    Topics: Antineoplastic Agents; Carcinogenesis; Humans; Neoplasms; Niacinamide; Nicotinamide N-Methyltransfer

2023
Nicotinamide and the skin.
    The Australasian journal of dermatology, 2014, Volume: 55, Issue:3

    Topics: Acne Vulgaris; Animals; Autoimmune Diseases; Carcinogenesis; Dermatitis, Atopic; Humans; Keratosis,

2014
The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.
    European journal of clinical investigation, 2015, Volume: 45, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins;

2015

Trials

2 trials available for niacinamide and Carcinogenesis

ArticleYear
A Reduction in Inflammatory Macrophages May Contribute to Skin Cancer Chemoprevention by Nicotinamide.
    The Journal of investigative dermatology, 2019, Volume: 139, Issue:2

    Topics: Carcinogenesis; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Count; Humans; Incidence; Macr

2019
A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).
    Lung cancer (Amsterdam, Netherlands), 2014, Volume: 83, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis Regulatory Proteins

2014

Other Studies

11 other studies available for niacinamide and Carcinogenesis

ArticleYear
Autophagy-inducing nutritional interventions in experimental and clinical oncology.
    International review of cell and molecular biology, 2022, Volume: 373

    Topics: Autophagy; Carcinogenesis; Humans; Medical Oncology; Methionine; Micronutrients; Neoplasms; Niacinam

2022
Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin.
    Nature communications, 2018, 01-31, Volume: 9, Issue:1

    Topics: Animals; Antineoplastic Agents; Carcinogenesis; Carcinoma, Hepatocellular; Glycolysis; Hep G2 Cells;

2018
Chemoprevention of Lung Carcinogenesis by Dietary Nicotinamide and Inhaled Budesonide.
    Cancer prevention research (Philadelphia, Pa.), 2019, Volume: 12, Issue:2

    Topics: Administration, Inhalation; Animals; Anti-Inflammatory Agents; Apoptosis; Benzo(a)pyrene; Budesonide

2019
Involvement of androgen receptor and glucose-regulated protein 78 kDa in human hepatocarcinogenesis.
    Experimental cell research, 2014, May-01, Volume: 323, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Cells, Cultured; Endopl

2014
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.
    Acta neuropathologica, 2014, Volume: 128, Issue:6

    Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Child, Preschool; Co

2014
BIRC6 promotes hepatocellular carcinogenesis: interaction of BIRC6 with p53 facilitating p53 degradation.
    International journal of cancer, 2015, Mar-15, Volume: 136, Issue:6

    Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Human

2015
Combinatorial chemopreventive effect of butyric acid, nicotinamide and calcium glucarate against the 7,12-dimethylbenz(a)anthracene induced mouse skin tumorigenesis attained by enhancing the induction of intrinsic apoptotic events.
    Chemico-biological interactions, 2015, Jan-25, Volume: 226

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Apoptosis; Apoptotic Protease-Ac

2015
Oct4 is a reliable marker of liver tumor propagating cells in hepatocellular carcinoma.
    Discovery medicine, 2015, Volume: 20, Issue:110

    Topics: Animals; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Separa

2015
(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.
    BMC cancer, 2016, Jan-19, Volume: 16

    Topics: Aged; Apoptosis; Carcinogenesis; Carcinoma, Squamous Cell; Female; Humans; Male; Middle Aged; Mutati

2016
Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 88

    Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cell Line, Tum

2017
The influence of nicotinamide and diphosphopyridine nucleotide on azo dye and methyl-cholanthrene carcinogenesis.
    Gan, 1960, Volume: 51

    Topics: Animals; Azo Compounds; Benz(a)Anthracenes; Carcinogenesis; Coloring Agents; Methylcholanthrene; NAD

1960